KR19980071084A - 사람 엔도글린 유전자의 프로모터 및 이의 용도 - Google Patents
사람 엔도글린 유전자의 프로모터 및 이의 용도 Download PDFInfo
- Publication number
- KR19980071084A KR19980071084A KR1019980003185A KR19980003185A KR19980071084A KR 19980071084 A KR19980071084 A KR 19980071084A KR 1019980003185 A KR1019980003185 A KR 1019980003185A KR 19980003185 A KR19980003185 A KR 19980003185A KR 19980071084 A KR19980071084 A KR 19980071084A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- promoter
- gene
- acid construct
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 101000881679 Homo sapiens Endoglin Proteins 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 239000012636 effector Substances 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 102000048896 human ENG Human genes 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 230000022131 cell cycle Effects 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 230000023555 blood coagulation Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 108010015046 cell aggregation factors Proteins 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 210000003705 ribosome Anatomy 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- -1 antibodies Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000002889 endothelial cell Anatomy 0.000 description 26
- 108010036395 Endoglin Proteins 0.000 description 20
- 108010047303 von Willebrand Factor Proteins 0.000 description 16
- 102100036537 von Willebrand factor Human genes 0.000 description 16
- 229960001134 von willebrand factor Drugs 0.000 description 16
- 102000012085 Endoglin Human genes 0.000 description 14
- 230000003511 endothelial effect Effects 0.000 description 10
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 9
- 239000003623 enhancer Substances 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 6
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 5
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 108091023043 Alu Element Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 102100033902 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000013128 Endothelin B Receptor Human genes 0.000 description 1
- 108010090557 Endothelin B Receptor Proteins 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 102000011852 GATA2 Transcription Factor Human genes 0.000 description 1
- 108010075641 GATA2 Transcription Factor Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 108050006616 Mannose-6-phosphate receptors Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19704301A DE19704301C1 (de) | 1997-02-06 | 1997-02-06 | Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie |
| DE19704301.1 | 1997-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR19980071084A true KR19980071084A (ko) | 1998-10-26 |
Family
ID=7819364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019980003185A Ceased KR19980071084A (ko) | 1997-02-06 | 1998-02-05 | 사람 엔도글린 유전자의 프로모터 및 이의 용도 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6103527A (enExample) |
| EP (1) | EP0857781A3 (enExample) |
| JP (1) | JPH11178A (enExample) |
| KR (1) | KR19980071084A (enExample) |
| CN (1) | CN1196784C (enExample) |
| AR (1) | AR011110A1 (enExample) |
| AU (1) | AU736724B2 (enExample) |
| BR (1) | BR9800563A (enExample) |
| CA (1) | CA2222981A1 (enExample) |
| CZ (1) | CZ289227B6 (enExample) |
| DE (1) | DE19704301C1 (enExample) |
| HU (1) | HUP9800247A3 (enExample) |
| PL (1) | PL324688A1 (enExample) |
| RU (1) | RU2230115C2 (enExample) |
| TR (1) | TR199800168A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19704301C1 (de) * | 1997-02-06 | 1998-03-26 | Hoechst Ag | Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie |
| CZ121599A3 (cs) | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
| DE60013586T2 (de) | 1999-04-02 | 2005-02-03 | Hisamitsu Pharmaceutical Co., Inc., Tosu | Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie |
| RU2295281C2 (ru) * | 2005-04-20 | 2007-03-20 | Федеральное государственное учреждение Научно-исследовательский институт детских инфекций, г.Санкт-Петербург | Способ оценки тяжести инфекционного поражения цнс у детей |
| RU2297848C2 (ru) * | 2005-05-11 | 2007-04-27 | Александр Веньяминович Иткес | Генно-инженерная конструкция vegf-ибмед (vegf-ibmed) |
| WO2009045370A2 (en) | 2007-09-28 | 2009-04-09 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
| US20110172293A1 (en) | 2008-07-08 | 2011-07-14 | Fish Jason E | Methods and Compositions for Modulating Angiogenesis |
| WO2014123749A1 (en) | 2013-01-30 | 2014-08-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for treating complications associated with diabetes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466596A (en) * | 1992-08-25 | 1995-11-14 | Mount Sinai Hospital Corporation | Tissue specific transcriptional regulatory element |
| WO1996006940A1 (de) * | 1994-08-26 | 1996-03-07 | Hoechst Aktiengesellschaft | Gentherapeutische behandlung von tumoren mit einem endothelzellspezifischen, zellzyklusabhängigen wirkstoff |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19704301C1 (de) * | 1997-02-06 | 1998-03-26 | Hoechst Ag | Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie |
-
1997
- 1997-02-06 DE DE19704301A patent/DE19704301C1/de not_active Expired - Fee Related
-
1998
- 1998-02-04 AR ARP980100497A patent/AR011110A1/es unknown
- 1998-02-04 CZ CZ1998332A patent/CZ289227B6/cs not_active IP Right Cessation
- 1998-02-04 TR TR1998/00168A patent/TR199800168A2/xx unknown
- 1998-02-04 CA CA002222981A patent/CA2222981A1/en not_active Abandoned
- 1998-02-05 BR BR9800563A patent/BR9800563A/pt not_active IP Right Cessation
- 1998-02-05 CN CNB981063500A patent/CN1196784C/zh not_active Expired - Fee Related
- 1998-02-05 AU AU52931/98A patent/AU736724B2/en not_active Ceased
- 1998-02-05 EP EP98102014A patent/EP0857781A3/de not_active Withdrawn
- 1998-02-05 KR KR1019980003185A patent/KR19980071084A/ko not_active Ceased
- 1998-02-05 HU HU9800247A patent/HUP9800247A3/hu not_active Application Discontinuation
- 1998-02-05 RU RU98101849/13A patent/RU2230115C2/ru not_active IP Right Cessation
- 1998-02-05 JP JP10024524A patent/JPH11178A/ja not_active Withdrawn
- 1998-02-06 US US09/019,689 patent/US6103527A/en not_active Expired - Fee Related
- 1998-02-06 PL PL98324688A patent/PL324688A1/xx unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466596A (en) * | 1992-08-25 | 1995-11-14 | Mount Sinai Hospital Corporation | Tissue specific transcriptional regulatory element |
| WO1996006940A1 (de) * | 1994-08-26 | 1996-03-07 | Hoechst Aktiengesellschaft | Gentherapeutische behandlung von tumoren mit einem endothelzellspezifischen, zellzyklusabhängigen wirkstoff |
Non-Patent Citations (2)
| Title |
|---|
| Bellon T et al, Eur J Immunol. 1993 Sep;23(9):2340-5 * |
| Cheifetz S et al, J Biol Chem. 1992 Sep 25;267(27):19027-30 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU736724B2 (en) | 2001-08-02 |
| BR9800563A (pt) | 1999-06-29 |
| CN1196784C (zh) | 2005-04-13 |
| HUP9800247A2 (hu) | 1998-10-28 |
| CA2222981A1 (en) | 1998-08-06 |
| RU2230115C2 (ru) | 2004-06-10 |
| EP0857781A3 (de) | 2001-05-16 |
| CZ289227B6 (cs) | 2001-12-12 |
| HUP9800247A3 (en) | 2002-11-28 |
| CN1203948A (zh) | 1999-01-06 |
| JPH11178A (ja) | 1999-01-06 |
| MX9800981A (es) | 1998-08-30 |
| CZ33298A3 (cs) | 1998-08-12 |
| HU9800247D0 (en) | 1998-03-30 |
| DE19704301C1 (de) | 1998-03-26 |
| AR011110A1 (es) | 2000-08-02 |
| PL324688A1 (en) | 1998-08-17 |
| EP0857781A2 (de) | 1998-08-12 |
| TR199800168A2 (xx) | 1998-08-21 |
| AU5293198A (en) | 1998-08-13 |
| US6103527A (en) | 2000-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Standke et al. | Mammary gland factor activated by prolactin on mammary epithelial cells and acute-phase response factor activated by interleukin-6 in liver cells share DNA binding and transactivation potential. | |
| Wilson et al. | A 58-base-pair region of the human C3 gene confers synergistic inducibility by interleukin-1 and interleukin-6 | |
| Pastorcic et al. | Control of transcription initiation in vitro requires binding of a transcription factor to the distal promoter of the ovalbumin gene | |
| Wenger et al. | The 5′ flanking region and chromosomal localization of the gene encoding human platelet membrane glycoprotein Ibα | |
| Ranganathan et al. | Cloning of murine tissue factor and regulation of gene expression by transforming growth factor type beta 1. | |
| Silins et al. | Analysis of the promoter region of the human VEGF-related factor gene | |
| KR19980071084A (ko) | 사람 엔도글린 유전자의 프로모터 및 이의 용도 | |
| EP0327369A2 (en) | Human plalelet-derived growth factor receptor | |
| TWI275644B (en) | Novel chimeric TNF ligands | |
| EP0859054B1 (en) | Drug binding protein | |
| US20030022827A1 (en) | Three new members of the cytokine receptor family class 2 | |
| CAMARA-CLAYETTE et al. | Transcriptional regulation of the KEL gene and Kell protein expression in erythroid and non-erythroid cells | |
| WO2000006759A9 (en) | Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same | |
| AU5318299A (en) | Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same | |
| Jolivet et al. | A MGF/STAT5 binding site is necessary in the distal enhancer for high prolactin induction of transfected rabbit αs1‐casein‐CAT gene transcription | |
| Hehlgans et al. | Activation of transcription by binding of NF-E1 (YY1) to a newly identified element in the first exon of the human DR alpha gene. | |
| MXPA98000981A (en) | Promoter of human endoglin gene and his | |
| Fey et al. | Gene regulation by interleukin 6 | |
| HK1017713A (en) | Promoter of the human endoglin gene and its use | |
| Düring et al. | Transcription factor USF from duck erythrocytes transactivates expression of the histone H5 gene in vitro by interacting with an intragenic sequence | |
| US7868154B2 (en) | Promoter to IL-18BP, its preparation and use | |
| Malecki et al. | In vivo study of angiogenic plasmid preparations—the bicistronic plasmid as a new type of drug for vascular diseases | |
| JP2005312304A (ja) | 新規インターフェロン制御因子活性化ポリペプチド及びそれをコードする核酸 | |
| Ofir et al. | Structural and functional analysis of the promoter of the murine Vγ1. 1 T cell receptor gene | |
| MAŁECKI et al. | Institute, Warsaw, Poland;'Department of Pharmacology, National Institute of Public |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19980205 |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20000814 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20030204 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19980205 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20050204 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20050601 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20050204 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |